Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation

Circulation

Volumn 104, Issue 12, 2001, Pages 1374-1379

  Frelinger III, Andrew L ^a,b   Furman, Mark I ^a   Krueger, Lori A ^a   Barnard, Marc R ^a   Michelson, Alan D ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Fibrinogen; Glycoproteins; Inhibitors; Platelets; Receptors

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN; THROMBIN; TIROFIBAN; XEMILOFIBAN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISSOCIATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

EID: 0035908999     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3701.095950     Document Type: Article

References (24)

1. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
2. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (IIbbeta3) inhibilors
3. Platelet GP IIb/IIIa blockers
4. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE Trial Investigators: Evaluation of oral xemilofiban in controlling thrombotic events
5. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
6. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
7. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient With Unstable Angina)
8. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials
9. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS TIMI 16) trial
10. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
11. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy: Orbofiban in patients with unstable coronary syndromes: Thrombolysis in myocardial infarction
12. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
13. Endogenous platelet fibrinogen surface expression on activated platelets
14. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function
15. Ligands "activate" integrin alpha IIb beta 3 (platelet GP IIb/IIIa)
16. Laboratory markers of platelet activation and their clinical significance
17. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
18. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
19. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
20. Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb-IIIa
21. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion
22. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers
23. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor
24. RGD peptides induce apoptosis by direct caspase-3 activation